Northwest Biotherapeutics (STU:NBYB) Short-Term Debt: €37.38 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NBYB Northwest Biotherapeutics Inc STU:NBYB
17 GF Score
Price €0.17
GF Value €0.24
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Northwest Biotherapeutics Short-Term Debt?

Northwest Biotherapeutics STU:NBYB -5.56% 17 Short-Term Debt is €37.38 Mil as of Mar. 2026. GuruFocus rates STU:NBYB with a GF Score™ of 17/100 and a GF Value™ of €0.24 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Northwest Biotherapeutics's Short-Term Debt for the quarter that ended in Mar. 2026 was €37.38 Mil.

Northwest Biotherapeutics's quarterly Short-Term Debt increased from Sep. 2025 (€34.42 Mil) to Dec. 2025 (€36.01 Mil) and increased from Dec. 2025 (€36.01 Mil) to Mar. 2026 (€37.38 Mil).

Northwest Biotherapeutics's annual Short-Term Debt increased from Dec. 2023 (€18.78 Mil) to Dec. 2024 (€32.83 Mil) and increased from Dec. 2024 (€32.83 Mil) to Dec. 2025 (€36.01 Mil).

Northwest Biotherapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Northwest Biotherapeutics Short-Term Debt Related Terms

Northwest Biotherapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics Short-Term Debt Chart

Northwest Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.41 14.67 18.78 32.83 36.01

Northwest Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.73 36.24 34.42 36.01 37.38
STU:NBYB
17GF Score
Northwest Biotherapeutics Inc STU:NBYB
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €37.38 Mil mean?
Northwest Biotherapeutics (STU:NBYB) has a Short-Term Debt of €37.38 Mil as of Mar. 2026.
Is Northwest Biotherapeutics' Short-Term Debt too high?
Northwest Biotherapeutics' current Short-Term Debt is €37.38 Mil. Overall, Northwest Biotherapeutics has a GF Score™ of 17/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Short-Term Debt compare to FATE and IMRX?
Northwest Biotherapeutics' Short-Term Debt of €37.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Northwest Biotherapeutics's current Short-Term Debt is €37.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Northwest Biotherapeutics (STU:NBYB) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.24, compared to a current price of €0.17 — trading 29.2% below its estimated fair value. The current Short-Term Debt is €37.38 Mil. Northwest Biotherapeutics' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Northwest Biotherapeutics (STU:NBYB), the current Short-Term Debt is €37.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Northwest Biotherapeutics (STU:NBYB) Overvalued in 2026?

Based on GuruFocus' analysis, Northwest Biotherapeutics stock appears to be undervalued. The current stock price of €0.17 is trading 29.2% below its estimated GF Value™ of €0.24. GuruFocus considers Northwest Biotherapeutics to be Modestly Undervalued.

Key valuation signals for STU:NBYB:

  • Short-Term Debt: €37.38 Mil
  • GF Value™: €0.24 vs. price of €0.17 (29.2% below fair value)
  • GF Score™: 17/100 with 5 warning signs

No single metric tells the full story. See the STU:NBYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Northwest Biotherapeutics Business Description

Other Exchanges NWBO:USA
Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
17GF Score

Get the complete analysis for STU:NBYB

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price
€0.24
GF Value